Stay updated on SAR422459 in Stargardt's Macular Degeneration Clinical Trial

Sign up to get notified when there's something new on the SAR422459 in Stargardt's Macular Degeneration Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the SAR422459 in Stargardt's Macular Degeneration Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent change in the webpage content.
    Difference
    0.1%
    Check dated 2024-06-13T21:18:24.000Z thumbnail image
  4. Check
    4 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value 7 has recently changed to 8 on the webpage, indicating a potential update in the study details related to the safety and tolerability assessment of ascending doses of SAR422459 in participants with Stargardt's Macular Degeneration (SMD). This change may reflect new information regarding the biological activity evaluation of SAR422459 in the context of the clinical trial.
    Difference
    0.1%
    Check dated 2024-06-06T14:26:05.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The 'Participation Criteria' section has been updated to include detailed eligibility criteria for participants, specifying inclusion and exclusion criteria for different participant groups in the study. Previously, no information was provided in this section.
    Difference
    50%
    Check dated 2024-05-22T20:55:19.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.9%
    Check dated 2024-04-30T22:41:07.000Z thumbnail image

Stay in the know with updates to SAR422459 in Stargardt's Macular Degeneration Clinical Trial

Enter your email address, and we'll notify you when there's something new on the SAR422459 in Stargardt's Macular Degeneration Clinical Trial page.